. OPT-80 is bactericidal, with a low propensity for resistance development (frequency, Ͻ2.8 ϫ 10
Ϫ8 at four and eight times the MIC) (22) .
Currently, most clinical microbiology laboratories do not routinely culture diarrheal stools for C. difficile or perform antimicrobial susceptibility testing on such isolates because of the time requirement, complexity, and expense of these procedures. However, because the inadequacy of current empirical therapies may be increasing and as the epidemiology and pathogenicity of C. difficile evolve (18) , periodic or routine surveillance of clinical isolates to determine their in vitro susceptibility profiles and studies determining the activities of investigational agents such as OPT-80 seem warranted. The purpose of the current study was to assess the in vitro activities of OPT-80 against a recent collection of 208 toxin-producing clinical isolates of C. difficile.
Bacterial isolates studied. Two hundred eight isolates of C. difficile from diarrheal toxin-positive stool specimens were cultured on Clostridium difficile moxalactam norfloxacin (CDMN) Selective Supplement agar (Oxoid Canada, Nepean, Ontario, Canada) following a 95% ethanol shock step (equal volumes of stool and 95% ethanol, gently mixed at 22 to 25°C for 1 h). Toxin production was determined using either the Triage Toxin A C. difficile panel enzyme immunoassay (Biosite Diagnostics, San Diego, CA) or the C. difficile Toxin/Antitoxin tissue culture assay (TechLab, Blacksburg, VA). All stool samples were collected from patients admitted to or seen at 1 of 2 urban tertiary-care teaching hospitals, 8 urban community hospitals, or 10 rural hospitals in the province of Manitoba, Canada, from January to April 2007. Each isolate's identity was confirmed by Gram staining, typical odor, latex agglutination (Microgen Bioproducts Ltd., Surrey, United Kingdom), and chartreuse fluorescence under UV light (16) .
Antimicrobial susceptibility testing. Susceptibility to 10 antimicrobial agents was tested using the agar dilution method recommended by the Clinical and Laboratory Standards Institute (CLSI) (4) . OPT-80 powder was provided by Optimer Pharmaceuticals, Inc.; powders of the other agents tested were provided by their respective manufacturers or were obtained from Sigma Chemical Company (St. Louis, MO). The solvent used for OPT-80 powder was dimethyl sulfoxide (DMSO); distilled sterile water was used as the diluent. C. difficile ATCC 700057 and/or Bacteroides fragilis ATCC 25285 was used as the control strain for amoxicillin-clavulanate, ceftriaxone, clindamycin, meropenem, metronidazole, moxifloxacin, piperacillintazobactam, and vancomycin testing (4) . The reference MIC range of OPT-80 for C. difficile ATCC 700057 was 0.06 to 0.25 g/ml (Optimer Pharmaceuticals, Inc.). The reference MIC range used for testing of rifampin against C. difficile ATCC 700057 was set at 0.004 to 0.03 g/ml, since no CLSI standard range exists (3). MICs were interpreted, when possible, using CLSI-recommended MIC breakpoints (4) .
Antimicrobial agent MIC ranges, modal MICs, concentrations inhibiting 50% (MIC 50 ) and 90% (MIC 90 ) of isolates tested, and MIC distributions for each agent tested are shown in Table 1 . OPT-80 MICs fell within a narrow range from 0.06 to 1 g/ml for the 208 isolates tested, with 90.9% (189/208) of MICs falling within the doubling dilution range of 0.125 and 0.5 g/ml. Based on MIC 90 data, rifampin had the highest in vitro potency of the 10 agents tested (MIC 90 , 0.015 g/ml), followed by OPT-80 (0.5 g/ml), metronidazole, vancomycin, and amoxicillin-clavulanate (1 g/ml), meropenem (2 g/ml), piperacillin-tazobactam (8 g/ml), and clindamycin, ceftriaxone, and moxifloxacin (Ͼ16 g/ml).
All 208 isolates tested were susceptible to metronidazole, amoxicillin-clavulanate, piperacillin-tazobactam, and meropenem by use of CLSI MIC interpretative criteria (4) . Isolate susceptibilities to moxifloxacin, clindamycin, and ceftriaxone were 46.2, 17.3, and 1.0%, respectively (4). OPT-80 MIC ranges, MIC modes, MIC 50 s, and MIC 90 s were identical for isolates susceptible and resistant to clindamycin and for those susceptible and resistant to moxifloxacin (data not shown). OPT-80 MICs for the six rifampin-resistant (MIC, Ͼ2 g/ml) isolates ranged from 0.125 to 0.5 g/ml, with a MIC of 0.25 g/ml for four isolates.
The MIC 50 (0.25 g/ml) and MIC 90 (0.5 g/ml) results generated by the current study of OPT-80 against clinical isolates of C. difficile are similar to those published in three earlier studies (MIC 50 , 0.125 to 0.25 g/ml; MIC 90 , 0.125 to 0.25 g/ml) (7, 9, 22) . In contrast, studies performed by Ackermann et al. (MIC 50 , 0.0019 g/ml; MIC 90 , 0.0078 g/ml) and Credito and Appelbaum (MIC 50 , Յ0.016 g/ml; MIC 90 , 0.125 g/ml) demonstrated OPT-80 to be more active (1, 5) ( Table 2 ). The observed variation may be due to differences in the solubility of OPT-80 in the diluent used in each study. In the study that reported the lowest MICs, OPT-80 was dissolved and diluted in DMSO; in the other studies, in which OPT-80 was dissolved in DMSO and diluted in water, higher MICs were obtained (1) . Another, less likely source of reported MIC differences may be agar dilution (5, 7, 9, 22; also the current study) versus broth (5, 7, 9 ; also the current study) seems less likely to be a source of OPT-80 MIC differences. OPT-80 is currently in phase 3 clinical trials for the treatment of C. difficile-associated diarrhea and colitis (13) . In clinical trials, OPT-80 has been dosed at 200 mg twice daily (400 mg/day). OPT-80 has been reported to be poorly absorbed by the gastrointestinal tract, with a maximum concentration in serum of 26.5 ng/ml reached after 1.5 h, and an apparent elimination half-life of 0.94 to 2.77 h was reported following a 400-mg dose (22) ; 92.6% of OPT-80 is recovered in feces (fecal drug level, 3,000 g/ml of dose) (7) primarily as its major metabolite, OP-1118, which is also biologically active (20) . In a hamster model for pseudomembranous colitis, OPT-80 completely prevented the lethality of the animals and prevented the occurrence of relapses (22) . The potential of OPT-80 to affect the resistance of normal gut flora to colonization is anticipated to be low (7) .
In conclusion, OPT-80 demonstrated potent in vitro activity (MIC 90 , 0.5 g/ml) against toxin-positive clinical isolates of C. difficile from Manitoba, Canada. OPT-80 may represent a future alternative to metronidazole and vancomycin for the treatment of CDAD.
